Nielsen E W, Stenberg P A, Einarsen E, Johansen H T, Mollnes T E
Anestesiavdelingen, Nordland sentralsykehus, Bodø.
Tidsskr Nor Laegeforen. 1994 Mar 10;114(7):804-6.
Angio-oedema as an adverse effect of angiotensin converting enzyme-inhibitors (ACE-inhibitors) is reported to occur in one to two of 1,000 treated patients per year. This estimate may be too low, since the swelling of face, lips, tongue and throat is very often attributed to food allergy. Furthermore, attacks of oedema may occur after months or even years of ACE-inhibitor treatment, thereby obscuring the link to the medication. This adverse effect is non-immunogenic. The oedema is explained by local enhancement of bradykinin, which under normal circumstances is broken down by angiotensin converting enzyme. The question of what makes some people vulnerable is still unsolved. The oedema can develop quickly and may lead to suffocation. In many cases, conventional antiallergic treatment in the form of steroids, antihistamines and epinephrine has inadequate effect. Intubation of the larynx may be necessary, but can be extremely difficult in the case of massive glassy oedema. Involvement of the neck can sometimes hinder tracheotomy, making early intervention essential. The authors describe two patients with moderate swellings, and discuss a potential, yet experimental, use of C1-inhibitor concentrate in the treatment of ACE-inhibitor provoked angioedema.
据报道,血管性水肿作为血管紧张素转换酶抑制剂(ACE抑制剂)的一种不良反应,在每年接受治疗的1000名患者中会有1至2人出现。这个估计可能偏低,因为面部、嘴唇、舌头和喉咙的肿胀常常被归因于食物过敏。此外,血管性水肿发作可能在ACE抑制剂治疗数月甚至数年之后出现,从而模糊了与药物的关联。这种不良反应是非免疫原性的。水肿是由缓激肽在局部增强引起的,在正常情况下缓激肽会被血管紧张素转换酶分解。有些人易患此病的原因仍未解决。水肿可能迅速发展并可能导致窒息。在许多情况下,采用类固醇、抗组胺药和肾上腺素形式的传统抗过敏治疗效果不佳。可能需要进行喉部插管,但在出现大量玻璃样水肿的情况下会极其困难。颈部受累有时会妨碍气管切开术,因此早期干预至关重要。作者描述了两名有中度肿胀的患者,并讨论了C1抑制剂浓缩物在治疗ACE抑制剂诱发的血管性水肿方面潜在但仍处于实验阶段的用途。